Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

Ipsen Exits Santhera Agreement on Fipamezole

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 25, 2012

Santhera Pharmaceuticals AG is looking for a new partner for its Parkinson's disease drug fipamezole after Ipsen SA returned its rights to the drug, which covered territories outside of North America and Japan.

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription

»

Login or register to post comments

Customer Service: In the U.S. and Canada: 1-800-688-2421
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 688-2421 or customerservice@bioworld.com.